Hims & Hers Health stock price forecast: sideways consolidation likely as HIMS falls 3.53%

Traders Union
All News
Financial News
Hims & Hers Health down 3.53% today

Highlights

HIMS is under sustained selling pressure, trading below all key moving averages and facing resistance at 20.93.
Momentum signals are broadly bearish, with weak trend and oversold conditions, suggesting limited buyer interest in the near term.
Expect the price to consolidate between 18.60 and 19.80 over the next five sessions, with a declining bias unless resistance is broken.

Bearish momentum holds as resistance and volatility shape trade

Technical signals remain weak for HIMS, with the Ichimoku Kijun at $20.93 marking immediate resistance above the last price. Momentum indicators (MACD, ADX) continue to show a selling bias, while daily RSI (43.33) and CCI (–93.24) signal a bearish tilt but stop short of clear oversold levels. Stoch RSI and BBP readings confirm oversold conditions, showing sellers in control, and the Awesome Oscillator remains neutral. Today’s session featured a gap down at the open (from $19.84 to $18.97), with the current price mid-session and volatility at moderate levels.

Sideways trading favored as breakout risk stays suppressed

Over the next five trading days, HIMS is likely to trade within a volatility band between $18.60 and $19.80 as dictated by recent swings. Major weekly trend and momentum signals suggest the chance of a price increase is below 20%, making further decline more likely. The base case scenario is for price to consolidate sideways within this corridor. A clear shift in tone would require a sustained move above $20.93, while a breakdown under $18.60 could accelerate bearish momentum.

Viktoras Karapetjanc, expert at Traders Union, notes that HIMS remains under pressure, with technical signals confirming continued weakness. He sees no fundamental or sentiment drivers to trigger a rebound in the current environment. The analyst believes consolidation is most likely, unless buyers reclaim control above $20.93. Momentum still favors sellers, but a break below $18.60 would increase downside risk. "I remain constructive overall, but buyers need to prove strength above $20.93 before optimism can return in the near term."

Earlier, analysts noted that Hims & Hers Health continued to face persistent selling pressure despite new product rollouts, with technical indicators signaling weakness. The current analysis reinforces this negative outlook, highlighting that a close below the $18.60 support could increase downside risk in the near term.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.